Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Clinical Trial
[키워드] 1:1
95% CI
95% confidence interval
acute respiratory syndrome
Ad26.COV2.S
Ad26.COV2.S vaccine
Adenovirus
adjusted
administration
assigned
Asymptomatic
coronavirus
coronavirus disease
death
development
disease
double-blind
effective
Efficacy
full-length
generally mild
Hospitalization
incidence
International
janssen
moderate
occurred
participant
per-protocol population
phase 3 trial
Placebo
placebo-controlled
primary end point
Randomized
Randomly
receive
Result
Safety
SARS-CoV-2
SARS-COV-2 infection
sequenced
Serious Adverse Event
single dose
South Africa
Spike protein
symptomatic COVID-19
tested
the placebo group
the vaccine
two groups
Vaccine
vaccine efficacy
Vaccines
variant
Viral particles
virus
[DOI] 10.1056/NEJMoa2101544 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2101544 PMC 바로가기 [Article Type] Clinical Trial